Mark W Hull
Overview
Explore the profile of Mark W Hull including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
701
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hannigan A, Krishnan N, Singh K, Bytelaar S, Schmitz D, Bartlett S, et al.
BMC Health Serv Res
. 2025 Feb;
25(1):243.
PMID: 39948586
Background: Despite rolling out publicly-funded hepatitis C virus (HCV) treatment across the province of British Columbia (BC), Canada, 35% of people returning positive HCV RNA results in 2020 did not...
2.
Grennan T, Mohammed S, Edward J, Tattersall T, Gupta A, Seto J, et al.
Clin Infect Dis
. 2025 Jan;
PMID: 39882974
Background: Men who have sex with men (MSM) and transgender women experience high sexually transmitted infection (STI) rates. This study evaluated the feasibility of doxycycline pre-exposure prophylaxis (doxyPrEP) for STI...
3.
Yuen A, Sang J, Wang L, Barath J, Lachowsky N, Lal A, et al.
Subst Use Misuse
. 2023 Oct;
59(2):278-290.
PMID: 37867395
Background: We explored attitudes of gay, bisexual, and other men who have sex with men (GBM) toward their amphetamine-use and associations with reduced use over time. Methods: We recruited sexually-active...
4.
Thompson K, Blank G, Toy J, Moore D, Lachowsky N, Bacani N, et al.
Liver Int
. 2022 Mar;
42(7):1528-1535.
PMID: 35274805
Background: Men who have sex with men (MSM) are at risk for sexually-transmitted hepatitis C (HCV). Evidence for HCV infection in the context of pre-exposure prophylaxis (PrEP) use in North...
5.
Thompson K, Blank G, Toy J, Moore D, Lachowsky N, Bacani N, et al.
Open Forum Infect Dis
. 2021 Nov;
8(11):ofab492.
PMID: 34805433
Initiation of human immunodeficiency virus preexposure prophylaxis (PrEP) medications will also treat hepatitis B infection (HBV). The prevalence of chronic HBV was 0.86% (n=41/4760) among enrollees in a provincial PrEP...
6.
Tan D, Tavangar F, Fusca L, Ross P, Hull M, Grennan T, et al.
Sex Transm Dis
. 2021 Jun;
48(8):e105-e108.
PMID: 34110756
We surveyed 383 men who have sex with men attending sexual health clinics regarding interest in hypothetical preexposure prophylaxis against herpes simplex virus. Overall interest was 62.5% and was associated...
7.
Eyawo O, Brockman G, Goldsmith C, Hull M, Lear S, Bennett M, et al.
BMJ Open
. 2019 Sep;
9(9):e025874.
PMID: 31551371
Objective: Cardiovascular disease (CVD) is one of the leading non-AIDS-defining causes of death among HIV-positive (HIV+) individuals. However, the evidence surrounding specific components of CVD risk remains inconclusive. We conducted...
8.
Tan D, Rolon M, Figueroa M, Sued O, Gun A, Kaul R, et al.
PLoS One
. 2019 Sep;
14(9):e0221653.
PMID: 31490959
Background: Inflammation has been associated with increased morbidity and mortality in HIV-positive patients. We compared inflammatory biomarkers with dual therapy using lopinavir/ritonavir plus lamivudine (LPV/r+3TC) versus triple therapy using LPV/r...
9.
St-Jean M, Tafessu H, Closson K, Patterson T, Lavergne M, Elefante J, et al.
Can J Public Health
. 2019 Aug;
110(6):779-791.
PMID: 31441005
Objective: Our primary objective was to examine the syndemic effect of HIV/HCV co-infection and mental health disorders (MHD) on the acute care hospitalization rate among people living with HIV (PLW-HIV)...
10.
Gali B, Eyawo O, Hull M, Samji H, Zhang W, Sereda P, et al.
Curr Med Res Opin
. 2019 Jul;
35(11):1955-1963.
PMID: 31315470
To characterize the incidence of select chronic comorbidities in the era of modern (pre-integrase-inhibitor) highly active antiretroviral therapy (HAART) in British Columbia, Canada. We used data from the Comparative Outcomes...